Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SGHT
Sight Sciences, Inc. (SGHT) P/E ratio
Sight Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 22 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SSII SS Innovations International, Inc. compare | n/m |
| SENS Senseonics Holdings, Inc. compare | n/m |
| SGHT Sight Sciences, Inc. | n/m |
| CERS Cerus Corporation compare | n/m |
| MASS 908 Devices Inc. compare | n/m |
| NPCE NeuroPace, Inc. compare | n/m |
| TCMD Tactile Systems Technology, Inc. compare | 20.5× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 24.8× |
| DCTH Delcath Systems, Inc. compare | 1,408× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)